InsiderSignal.AI

InsiderSignal.ai

LRMR - Larimar Therapeutics, Inc.

Insider Purchase by Hamilton Thomas Edward (Dir)

3 Months
After Trade
Before Trade

Loading data...

Trade Summary

1 month ago, Hamilton Thomas Edward, serving as Dir at Larimar Therapeutics, Inc. (LRMR), purchased 100,000 shares at $5.00 per share, for a total transaction value of $500,000.00. Following this transaction, Hamilton Thomas Edward now holds 824,231 shares of LRMR.

This purchase represents a 14.00% increase in Hamilton Thomas Edward's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Friday, February 27, 2026 and publicly disclosed via SEC Form 4 filing on Monday, March 2, 2026, 3 days after the trade was made.

Larimar Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Hamilton Thomas Edward

Dir

Thomas Edward Hamilton is a Director of Larimar Therapeutics, Inc., a pharmaceutical company specializing in therapeutic preparations[[1]](https://theorg.com/org/larimar-therapeutics/org-chart/tom-hamilton)[[2]](https://in.marketscreener.com/insider/THOMAS-HAMILTON-A1B47L/). He serves as President, Chief Executive Officer, and owner of Construction Forms, Inc. (Con Forms), an industrial manufacturing company based in Port Washington, Wisconsin[[1]](https://theorg.com/org/larimar-therapeutics/org-chart/tom-hamilton). Hamilton is also a managing member of FA Life Sciences, an early-stage biotech investment company focused on advancing treatments for Friedreich's ataxia, and serves as a Director and Executive Committee member of the Friedreich's Ataxia Research Alliance (FARA)[[1]](https://theorg.com/org/larimar-therapeutics/org-chart/tom-hamilton). Additionally, he is Co-founder of the CureFA Foundation, a nonprofit research organization dedicated to developing a cure for Friedreich's Ataxia[[6]](https://larimartx.com/team/tom-hamilton/). Hamilton brings extensive financial expertise from his career in capital markets, having served as a managing director and strategic advisor to the head of fixed income, currencies, and commodities at Barclays Capital in New York, where he led the development of Global Securitized Products businesses, Municipal Trading, and Investment Banking[[1]](https://theorg.com/org/larimar-therapeutics/org-chart/tom-hamilton)[[6]](https://larimartx.com/team/tom-hamilton/). Prior to Barclays, he held positions at Citigroup Global Markets and began his career at Salomon Brothers, Inc. in New York[[1]](https://theorg.com/org/larimar-therapeutics/org-chart/tom-hamilton)[[6]](https://larimartx.com/team/tom-hamilton/). As of February 2026, Hamilton owns 664,798 shares of Larimar Therapeutics directly and holds an additional 159,433 shares indirectly through Post Edison, LLC, demonstrating significant commitment to the company's success[[5]](https://www.stocktitan.net/sec-filings/LRMR/form-4-larimar-therapeutics-inc-insider-trading-activity-01b5c47a0934.html).

View full insider profile →

Trade Price

$5.00

Quantity

100,000

Total Value

$500,000.00

Shares Owned

824,231

Trade Date

Friday, February 27, 2026

51 days ago

SEC Filing Date

Monday, March 2, 2026

Filed 3 days after trade

HEALTHCAREBIOTECHNOLOGY

About Larimar Therapeutics, Inc.

Company Overview

No company information available
View news mentioning LRMR

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/4439652

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime